Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alxoid
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Alxoid is a subcutaneous immunotherapy product containing one or several standardized polymerized allergen extracts adsorbed onto aluminium hydroxide gel. It is indicated for the treatment of type I (IgE-mediated) allergic diseases such as rhinitis, conjunctivitis, and asthma in adults and children over 5 years old. The allergens can include mixtures such as Dermatophagoides pteronyssinus and Dermatophagoides farinae (house dust mites), or grass pollen mixtures. The therapy works by gradually exposing the immune system to increasing doses of the relevant allergen(s), aiming to induce tolerance and reduce allergic symptoms over time. Administration must be performed by trained healthcare professionals in medical facilities equipped for emergency management of severe allergic reactions[3][7][1].
- Brand names
- Alxoid
- Other names
- ClustekCluster-allergoidCLUSTOID
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on Alxoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alxoid.